Cargando…

Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD

Detalles Bibliográficos
Autor principal:	Ray, Katrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	In Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008329/ https://www.ncbi.nlm.nih.gov/pubmed/33785883 http://dx.doi.org/10.1038/s41575-021-00445-1

Ejemplares similares

Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients
por: Spencer, Elizabeth A, et al.
Publicado: (2021)

Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic
por: Mastronardi, Mauro, et al.
Publicado: (2020)

Antibody responses to SARS-CoV-2 short-lived
por: Vabret, Nicolas
Publicado: (2020)

Anti–SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?
por: Chapman, Thomas P., et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 — sustained after all?
por: Compeer, Ewoud B., et al.
Publicado: (2020)

Multiple sclerosis treatment blunts SARS-CoV-2 antibody response
por: Lemprière, Sarah
Publicado: (2021)

Antibody Responses One Year after Mild SARS-CoV-2 Infection
por: Choe, Pyoeng Gyun, et al.
Publicado: (2021)

SARS-CoV-2 antibody seroconversion in care home
por: Shang, Joan, et al.
Publicado: (2020)

SARS-CoV-2-specific T cells without antibodies
por: Bozkus, Cansu Cimen
Publicado: (2020)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx
por: Sydney, Elana R., et al.
Publicado: (2020)

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
por: Liu, Zhigang, et al.
Publicado: (2023)

The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients
por: Higgins, Peter D R, et al.
Publicado: (2020)

The impact of SARS-CoV-2 variants on IBD management
por: Segal, Jonathan P, et al.
Publicado: (2021)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
por: Hocher, Berthold, et al.
Publicado: (2022)

SARS-CoV-2 variant evades antibodies whilst maintaining fitness
por: Flemming, Alexandra
Publicado: (2021)

IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
por: Choudhary, Hari Ram, et al.
Publicado: (2021)

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
por: Dashdorj, Naranjargal J., et al.
Publicado: (2021)

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
por: Bakasis, Athanasios-Dimitrios, et al.
Publicado: (2022)

The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios
por: Kotsiou, Ourania S., et al.
Publicado: (2022)

Spatial resolution of SARS-CoV-2 lung infection
por: Pia, Luisanna
Publicado: (2020)

Soluble ACE2 in SARS-CoV-2 infection
por: Allison, Susan
Publicado: (2021)

Bayesian estimation of the seroprevalence of antibodies to SARS-CoV-2
por: Dong, Qunfeng, et al.
Publicado: (2020)

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections
por: Lv, Huibin, et al.
Publicado: (2020)

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
por: Lv, Huibin, et al.
Publicado: (2020)

SARS-CoV-2 IgG Antibody Levels in Women with IBD Vaccinated during Pregnancy
por: Avni Biron, Irit, et al.
Publicado: (2022)

Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic
por: Choe, Pyoeng Gyun, et al.
Publicado: (2022)

Implications of recurrent SARS-CoV-2 outbreaks for IBD management
por: Segal, Jonathan P, et al.
Publicado: (2020)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis
por: Sharma, Pragya, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study
por: Kaplan, Gilaad G, et al.
Publicado: (2022)

Harmonization of Determination of SARS-CoV-2 Antibodies: Is It Always Possible?
por: Dittadi, Ruggero
Publicado: (2022)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Serological Detection of SARS-CoV-2 Antibodies in Naturally-Infected Mink and Other Experimentally-Infected Animals
por: Berguido, Francisco J., et al.
Publicado: (2021)

Serological response to SARS‐CoV‐2 is attenuated in patients with inflammatory bowel disease and can affect immunization
por: Ghavami, Shaghayegh Baradaran, et al.
Publicado: (2022)

No indication for SARS-CoV-2 transmission to pet ferrets, in five cities in Poland, 2021 - antibody testing among ferrets living with owners infected with SARS-CoV-2 or free of infection
por: Kaczorek-Łukowska, Edyta, et al.
Publicado: (2023)

The Antibody Response to SARS-CoV-2 Infection
por: Hueston, Linda, et al.
Publicado: (2020)

Attacking the defence: SARS-CoV-2 can infect immune cells
por: Borsa, Mariana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8m5mn8gc0hp967f1u19s9g7l25